TRAUMA PRIMES CELLS

创伤引发细胞

基本信息

  • 批准号:
    6919553
  • 负责人:
  • 金额:
    $ 43.28万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1998
  • 资助国家:
    美国
  • 起止时间:
    1998-04-01 至 2005-03-31
  • 项目状态:
    已结题

项目摘要

This current application is conceived as an extension of our funded 1998 Trauma Center application. Our GLOBAL HYPOTHESIS is that we can devise THERAPY FOR TRAUMA PRIMES CELLS. During the past two years, we have enjoyed gratifying recruitment of patients into our Trauma/MOF Registries (ADULTS-Project IA and Children-Project 1C) and we postulate that polymorphisms in the promoter region of stress- response genes influence the susceptibility to post-injury MOF (Project 1B). Activated neutrophils have traditionally been linked to post-injury systemic inflammation and we postulate an exacerbation of this injury due to delayed neutrophil apoptosis (Project II). Cells/organs/patient ischemia is the hallmark of any major injury and we wish to explore this altered cellular bioenergic profile as signal dictating post-traumatic events (Project III). We expand our previous interrogation of signaling mechanisms to an examination of mechanisms of hyperosmolar therapy (Project IV). Liposomal delivery of HSP72 inhibits Mphi TNF production. We further propose that HSP72 suppresses TNF receptor mediated amplification of Mphi inflammatory response and that targeted deliver of HSP72 controls post-injury myocardial inflammation (Project V). Lung dysfunction is acknowledged by an early victim in the sequential cascade of post-injury organ failure. We propose pulmonary vasomotor dysfunction to be the origin of this clinically frightening problem (Project VI). TNF (although immunologically healthy) is now recognized for its post-injury depressive potential. We propose both mechanisms of and therapy against interleukin-18 as an even more proximal "out of control" cytokine (Project VII). Two years ago, we proposed kinase/phosphatase signaling as the backbone of post-injury cellular message transmission. We now postulate that sarcolemmal signal endocytosis onto a cytoskeletal scaffolding regulates the sequence and magnitude of post-injury information transfer (Project VIII). To our surprise, blood transfusion (which we had happily translated as a surrogate for shock) proved to be an independent predictor of post- traumatic MOF. We now postulate that the oxygen carrying hemoglobin is good; but, the red cell membrane lipid bits are bad. We propose to decipher which membrane lipid parts cause trouble (Project IX) and further we will conduct clinical anti-cytokine trials (Projects VI and VII) (no funding requested) and a resuscitative trial with a hemoglobin based oxygen carrier (no funding requested) which we hope will bypass a problem (blood transfusion) that we identified in our early Trauma Registry (Project IA).
目前的申请被认为是我们1998年资助的创伤中心申请的延伸。我们的总体假设是,我们可以设计出治疗创伤启动细胞的方法。在过去的两年中,我们很高兴地将患者招募到我们的创伤/MOF登记处(成人- IA项目和儿童- 1C项目),我们假设应激反应基因启动子区域的多态性影响损伤后MOF的易感性(1B项目)。传统上,活化的中性粒细胞与损伤后全身性炎症有关,我们假设由于中性粒细胞凋亡延迟,这种损伤会加剧(项目II)。细胞/器官/患者缺血是任何重大损伤的标志,我们希望探索这种改变的细胞生物能量谱作为指示创伤后事件的信号(项目三)。我们将之前对信号机制的研究扩展到对高渗治疗机制的研究(项目四)。脂质体递送HSP72抑制Mphi TNF的产生。我们进一步提出HSP72抑制TNF受体介导的Mphi炎症反应的扩增,并且靶向递送HSP72控制损伤后心肌炎症(项目V)。肺功能障碍是公认的早期受害者在损伤后器官衰竭的顺序级联。我们认为肺血管舒缩功能障碍是这一临床可怕问题的根源(项目六)。TNF(虽然免疫上是健康的)现在被认为具有损伤后抑郁的潜力。我们提出了白细胞介素-18作为一种更接近“失控”的细胞因子的机制和治疗方法(项目七)。两年前,我们提出了激酶/磷酸酶信号作为损伤后细胞信息传递的主干。我们现在假设细胞骨架支架上的肌上皮信号内吞作用调节损伤后信息传递的顺序和强度(项目VIII)。令我们惊讶的是,输血(我们很高兴地将其翻译为休克的替代品)被证明是创伤后MOF的独立预测因子。我们现在假设携带氧气的血红蛋白是好的;但是,红细胞膜脂质位是坏的。我们建议解密哪些膜脂部分会引起麻烦(项目IX),进一步我们将进行临床抗细胞因子试验(项目VI和VII)(不需要资金)和基于血红蛋白的氧载体的复苏试验(不需要资金),我们希望能绕过我们在早期创伤登记(项目IA)中发现的问题(输血)。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ANIRBAN BANERJEE其他文献

ANIRBAN BANERJEE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ANIRBAN BANERJEE', 18)}}的其他基金

Project 3: Anti-Inflammatory Mechanisms of Inhaled Hypertonic Saline
项目3:吸入高渗盐水的抗炎机制
  • 批准号:
    8382283
  • 财政年份:
    2012
  • 资助金额:
    $ 43.28万
  • 项目类别:
Trauma Primes Cells
创伤引发细胞
  • 批准号:
    8069421
  • 财政年份:
    2010
  • 资助金额:
    $ 43.28万
  • 项目类别:
CORE--CELL AND IMAGING
核心——细胞与成像
  • 批准号:
    6973946
  • 财政年份:
    2005
  • 资助金额:
    $ 43.28万
  • 项目类别:
POST-ENDOCYTOTIC INFLAMMATORY SIGNALING AFTER TRAUMA
创伤后内吞后炎症信号传导
  • 批准号:
    6919600
  • 财政年份:
    2005
  • 资助金额:
    $ 43.28万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    6919601
  • 财政年份:
    2005
  • 资助金额:
    $ 43.28万
  • 项目类别:
Core--Cytoskeletal Facility
核心--细胞骨架设施
  • 批准号:
    6660107
  • 财政年份:
    2002
  • 资助金额:
    $ 43.28万
  • 项目类别:
Core--Cytoskeletal Facility
核心--细胞骨架设施
  • 批准号:
    6585990
  • 财政年份:
    2002
  • 资助金额:
    $ 43.28万
  • 项目类别:
CALCIUM ION DEPENDENT PHOSPHOKINASE C ISOFORMS IN ADAPTATION/INFLAMATION
适应/炎症中钙离子依赖性磷酸激酶 C 亚型
  • 批准号:
    6340978
  • 财政年份:
    2000
  • 资助金额:
    $ 43.28万
  • 项目类别:
CALCIUM ION DEPENDENT PHOSPHOKINASE C ISOFORMS IN ADAPTATION/INFLAMATION
适应/炎症中钙离子依赖性磷酸激酶 C 亚型
  • 批准号:
    6296720
  • 财政年份:
    1999
  • 资助金额:
    $ 43.28万
  • 项目类别:
CALCIUM ION DEPENDENT PHOSPHOKINASE C ISOFORMS IN ADAPTATION/INFLAMATION
适应/炎症中钙离子依赖性磷酸激酶 C 亚型
  • 批准号:
    6107678
  • 财政年份:
    1999
  • 资助金额:
    $ 43.28万
  • 项目类别:

相似海外基金

Neutrophil extracellular traps contribute multiple organ failure after traumatic brain injury
中性粒细胞胞外陷阱导致脑外伤后多器官衰竭
  • 批准号:
    21K17324
  • 财政年份:
    2021
  • 资助金额:
    $ 43.28万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of activity of HMGB1 and therapeutic prospects in multiple organ failure caused by traumatic hemorrhagic shock
HMGB1活性的阐明和创伤失血性休克引起的多器官功能衰竭的治疗前景
  • 批准号:
    19K18337
  • 财政年份:
    2019
  • 资助金额:
    $ 43.28万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
A Device for the Prevention and Treatment of Multiple Organ Failure in COVID-19 Patients
用于预防和治疗 COVID-19 患者多器官衰竭的设备
  • 批准号:
    10165404
  • 财政年份:
    2017
  • 资助金额:
    $ 43.28万
  • 项目类别:
Novel therapeutic strategy for septic multiple organ failure by suppressing NET formation
通过抑制 NET 形成治疗脓毒症多器官衰竭的新策略
  • 批准号:
    17K17072
  • 财政年份:
    2017
  • 资助金额:
    $ 43.28万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Inflammation Phenotypes in Pediatric Sepsis Induced Multiple Organ Failure
小儿脓毒症引起的多器官衰竭的炎症表型
  • 批准号:
    8795738
  • 财政年份:
    2014
  • 资助金额:
    $ 43.28万
  • 项目类别:
Inflammation Phenotypes in Pediatric Sepsis Induced Multiple Organ Failure Renewal
小儿脓毒症引起的多器官衰竭更新的炎症表型
  • 批准号:
    10207661
  • 财政年份:
    2014
  • 资助金额:
    $ 43.28万
  • 项目类别:
Inflammation Phenotypes in Pediatric Sepsis Induced Multiple Organ Failure Renewal
小儿脓毒症引起的多器官衰竭更新的炎症表型
  • 批准号:
    10458632
  • 财政年份:
    2014
  • 资助金额:
    $ 43.28万
  • 项目类别:
Inflammation Phenotypes in Pediatric Sepsis Induced Multiple Organ Failure
小儿脓毒症引起的多器官衰竭的炎症表型
  • 批准号:
    8610429
  • 财政年份:
    2014
  • 资助金额:
    $ 43.28万
  • 项目类别:
Efficacy of alginic acid for the treatment of multiple organ failure in sepsis
海藻酸治疗脓毒症多器官功能衰竭的疗效
  • 批准号:
    26860116
  • 财政年份:
    2014
  • 资助金额:
    $ 43.28万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Inflammation Phenotypes in Pediatric Sepsis Induced Multiple Organ Failure Renewal
小儿脓毒症引起的多器官衰竭更新的炎症表型
  • 批准号:
    10017690
  • 财政年份:
    2014
  • 资助金额:
    $ 43.28万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了